Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers

Biomedical Chromatography

Volumn 25, Issue 10, 2011, Pages 1112-1123

  de Boer, Theo ^a   Wieling, Jaap ^a   Meulman, Erik ^a   Reuvers, Mariska ^a   Renkema, Gonda ^a   den Daas, Izaak ^a   van Iersel, Thijs ^a   Wemer, Johan ^a   Chen, Lingsing ^b  

^a QPS Netherlands   (Netherlands)

^b QPS LLC   (United States)

Author keywords

DBS LC MS MS; Dried blood spot(s) (DBS); Genotyping; Limited sampling techniques; Midazolam; Phenotyping

Indexed keywords

BLOOD; PLASMA STABILITY;

DRIED BLOOD SPOT(S) (DRIED BLOOD SPOT); DRIED BLOOD SPOT-LC-MS/MS; GENOTYPING; LC-MS-MS; LC.MS/MS; LIMITED SAMPLING TECHNIQUE; MIDAZOLAM; PHENOTYPING; SAMPLING TECHNIQUE; WHOLE BLOOD;

ENZYMES;

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MIDAZOLAM; MIDAZOLAM MALEATE;

ADULT; ARTICLE; BLOOD SAMPLING; DRIED BLOOD SPOT SAMPLING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHENOTYPE; PHLEBOTOMIST; SINGLE DRUG DOSE; STRUCTURED QUESTIONNAIRE; VEIN PUNCTURE;

EID: 80052537545     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1580     Document Type: Article

References (12)

1. Edelbroek PM, van der Heijden J and Stolk LML. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Therapeutic Drug Monitoring 2009; 3: 327-336.
2. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research: Rockville, MD, 2001.
3. Hollegaard MV, Grove J, Thorsen P, Nørgaard-Pedersen B and Hougaard DM. High-throughput genotyping on archived dried blood spot samples. Genetic Testing and Molecular Biomarkers 2009; 13: 173-179.
4. Lee LL, Bertino JS and Nafziger AN. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A Activity. Journal of Clinical Pharmacology 2006; 46: 229-234.
5. Li W and Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomedical Chromatography 2010; 24: 49-65.
6. Morello R, Berger I, Kinzig M and Boos KS. LC-MS/MS analysis of immunosuppressants in whole blood: comparison of dried blood spots, heat-shock or cryogenically treated blood and denatured blood. Poster at EBF Workshop, Connecting Strategies on Dried Blood Spots, 17-18 June 2010.
7. Rowland M and Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. The AAPS Journal. 2010; 12: 290-293.
8. Shah VP, Midha KK, Findlay JWA et al. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research, 2000; 17: 1551-1557.
9. Spooner N, Lad R and Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Analytical Chemistry 2009; 81: 1557-1563.
10. Tump C, Hilhorst MJ, Ooms JA and Wieling J. Direct, on-site, on-cartridge toxicokinetic sampling prior to on-line SPE: a feasibility study. Chromatographia 2004; 59: 1-5.
11. Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research 2007; 24: 1962-1973.
12. Wijnen PA, Op den Buijsch RA, Cheung SC et al. Genotyping with a dried blood spot method: a useful technique for application in pharmacogenetics. Clinica Chimica Acta 2007; 388: 189-191.